Social Security makes it easier for people with severe medical conditions to access disability benefits by adding 13 diseases to the list.

NXC-201 is currently being evaluated in AL amyloidosis within a Phase Ib/II trial, but Immix plans to test it in other, undisclosed serious diseases.

GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials. The Danish pharma said that the Phase II trial of coramitug (PRX004), an mAb ...

A recent study led by a team of researchers at The Johns Hopkins University School of Medicine examining aging mice has ...

A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors.

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results Alnylam’s CEO claimed ...

AA amyloidosis follows any number of inflammatory diseases, including classical rheumatologic diseases such as rheumatoid arthritis (RA), as well as "auto-inflammatory" conditions such as familiar ...

PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Next program update Q1 2025 AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow affecting ~33,000 patients in the U.S.

The Takeaway It may be difficult to talk to your family about hereditary ATTR amyloidosis, but it enables your loved ones to take informed steps to protect their health.